"The development of the Teoxane RHA ® Collection with Mepivacaine exemplifies Teoxane's commitment to innovation," states Valérie Taupin, Founder and CEO of Teoxane. "Mepivacaine represents the first ...
NASHVILLE, Tenn., Jan. 13, 2026 /PRNewswire/ -- Revance and Teoxane announce the FDA approval of RHA ® Dynamic Volume from the Teoxane RHA ® Collection for cheek augmentation and/or the correction of ...
– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023 product revenue ...
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that its data will be featured during the 2021 Virtual ...
According to the terms of the deal, Crown will buy Revance at $3.65 per share At the closing, Revance will no longer trade on the Nasdaq Revance’s portfolio includes Daxxify for injection and the RHA ...
Teoxane today announced the publication in the Aesthetic Surgery Journal of a pivotal randomized, controlled, double-blinded trial evaluating the safety and effectiveness of RHA® 3 for lip ...
– Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately 28% and 80% YoY growth, respectively. – Q4 DAXXIFY volume up 22% ...
- Supports Revance’s commitment to ensuring safety and efficacy of aesthetic product portfolio among diverse patient populations - NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results